ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Sodium butyrate induces apoptosis enhanced by JAK2 inhibitor Fedratinib in NK/T-cell lymphoma cell.
Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundNK/T-cell lymphoma (NKTCL) is a malignant tumor associated with Epstein-Barr virus (EBV) infection. Histone acetylation, which can regulate gene expression, plays a crucial role in epigenetic control. Sodium butyrate (NaB), a nonspecific inhibitor of histone deacetylase (HDAC), has antitumor effects on various malignancies. However, the mechanism of NaB in NKTCL remains poorly understood.
methodsNKTCL cells were treated with specified concentrations of NaB for designated durations. Cell viability was assessed using the CCK-8 method, whereas flow cytometry was used to evaluate apoptosis and the cell cycle. RT-qPCR and western blot analyses were conducted to measure the expression levels of genes associated with the cell cycle, apoptosis, autophagy, HDAC, EBV, and molecules in the PI3K/Akt/mTOR and JAK/STAT signaling pathways.
resultsNaB downregulated the expression of HDAC 3, 4, 5, 8, 9, and 10 in NKTCL cell lines, leading to a significant reduction in cell viability and G
conclusionsNaB effectively promotes apoptosis and inhibits the JAK/STAT signaling pathway in NKTCL, which is further promoted by the JAK2 inhibitors fedratinib. Furthermore, NaB induces EBV reactivation and lytic infection in NKTCL, suggesting its ability to transition EBV from a latent to a lytic form.
Indexed as
Identifiers
41621012What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.